Alshehri Faez Falah
Department of Medical Laboratories, College of Applied Medical Sciences, Ad Dawadimi 17464, Shaqra University, Saudi Arabia.
Saudi Pharm J. 2023 Dec;31(12):101835. doi: 10.1016/j.jsps.2023.101835. Epub 2023 Oct 20.
Epilepsy, a prevalent chronic disorder of the central nervous system, is typified by recurrent seizures. Present treatments predominantly offer symptomatic relief by managing seizures, yet fall short of influencing epileptogenesis. This study endeavored to identify novel phytochemicals with potential therapeutic efficacy against S100B, an influential protein in epileptogenesis, through an innovative application of machine learning-enabled virtual screening. Our study incorporated the use of multiple machine learning algorithms, including Support Vector Machine (SVM), k-Nearest Neighbors (kNN), Naive Bayes (NB), and Random Forest (RF). These algorithms were employed not only for virtual screening but also for essential feature extraction and selection, enhancing our ability to distinguish between active and inactive compounds. Among the tested machine learning algorithms, the RF model outshone the rest, delivering an impressive 93.43 % accuracy on both training and test datasets. This robust RF model was leveraged to sift through the library of 9,000 phytochemicals, culminating in the identification of 180 potential inhibitors of S100B. These 180 active compounds were than docked with the active site of S100B proteins. The results of our study highlighted that the 6-(3,12-dihydroxy-4,10,13-trimethyl-7,11-dioxo-2,3,4,5,6,12,14,15,16,17-decahydro-1H cyclopenta[a] phenanthren -17-yl)-2-methyl-3-methylideneheptanoic acid, rhinacanthin K, thiobinupharidine, scopadulcic acid, and maslinic acid form significant interactions within the binding pocket of S100B, resulting in stable complexes. This underscores their potential role as S100B antagonists, thereby presenting novel therapeutic possibilities for epilepsy management. To sum up, this study's deployment of machine learning in conjunction with virtual screening not only has the potential to unearth new epilepsy therapeutics but also underscores the transformative potential of these advanced computational techniques in streamlining and enhancing drug discovery processes.
癫痫是一种常见的中枢神经系统慢性疾病,其特征为反复发作的癫痫发作。目前的治疗主要通过控制癫痫发作来提供症状缓解,但在影响癫痫发生方面仍有不足。本研究致力于通过创新应用机器学习驱动的虚拟筛选,识别对S100B具有潜在治疗效果的新型植物化学物质,S100B是癫痫发生中一种有影响力的蛋白质。我们的研究使用了多种机器学习算法,包括支持向量机(SVM)、k近邻算法(kNN)、朴素贝叶斯(NB)和随机森林(RF)。这些算法不仅用于虚拟筛选,还用于关键特征提取和选择,提高了我们区分活性和非活性化合物的能力。在测试的机器学习算法中,RF模型表现优于其他算法,在训练数据集和测试数据集上的准确率均达到了令人印象深刻的93.43%。利用这个强大的RF模型对9000种植物化学物质的库进行筛选,最终确定了180种潜在的S100B抑制剂。然后将这180种活性化合物与S100B蛋白的活性位点进行对接。我们的研究结果突出表明,6-(3,12-二羟基-4,10,13-三甲基-7,11-二氧代-2,3,4,5,6,12,14,15,16,17-十氢-1H-环戊并[a]菲-17-基)-2-甲基-3-亚甲基庚酸、刺蒴麻素K、硫代荷叶碱、苦玄参酸和山楂酸在S100B的结合口袋内形成显著相互作用,形成稳定的复合物。这突出了它们作为S100B拮抗剂的潜在作用,从而为癫痫治疗提供了新的治疗可能性。总之,本研究将机器学习与虚拟筛选相结合,不仅有可能挖掘出新的癫痫治疗方法,还强调了这些先进计算技术在简化和加强药物发现过程中的变革潜力。